Poly Medicure Beheer

Beheer criteriumcontroles 2/4

De CEO Poly Medicure is Himanshu Baid, benoemd in Sep1995, heeft een ambtstermijn van 29.17 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 171.78M, bestaande uit 33.6% salaris en 66.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 11.59% van de aandelen van het bedrijf, ter waarde ₹ 30.58B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.4 jaar en 8.4 jaar.

Belangrijke informatie

Himanshu Baid

Algemeen directeur

₹171.8m

Totale compensatie

Percentage CEO-salaris	33.6%
Dienstverband CEO	29.2yrs
Eigendom CEO	11.6%
Management gemiddelde ambtstermijn	6.4yrs
Gemiddelde ambtstermijn bestuur	8.4yrs

Recente managementupdates

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22

Recent updates

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 12

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Oct 14

Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt

Jul 07

Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends

Jun 18

Poly Medicure's (NSE:POLYMED) Solid Profits Have Weak Fundamentals

May 31

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹1,195

May 26

Analyse CEO-vergoeding

Hoe is Himanshu Baid's beloning veranderd ten opzichte van Poly Medicure's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹3b
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹172m	₹58m	₹3b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	n/a	n/a	₹2b
Mar 31 2023	₹130m	₹55m	₹2b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹1b
Jun 30 2022	n/a	n/a	₹1b
Mar 31 2022	₹107m	₹49m	₹1b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹1b
Jun 30 2021	n/a	n/a	₹1b
Mar 31 2021	₹92m	₹44m	₹1b
Dec 31 2020	n/a	n/a	₹1b
Sep 30 2020	n/a	n/a	₹1b
Jun 30 2020	n/a	n/a	₹1b
Mar 31 2020	₹62m	₹35m	₹959m
Dec 31 2019	n/a	n/a	₹947m
Sep 30 2019	n/a	n/a	₹858m
Jun 30 2019	n/a	n/a	₹719m
Mar 31 2019	₹44m	₹14m	₹654m
Mar 31 2018	₹41m	₹14m	₹706m

Compensatie versus markt: De totale vergoeding ($USD 2.03M ) Himanshu } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 618.18K ).

Compensatie versus inkomsten: De vergoeding van Himanshu is het afgelopen jaar met meer dan 20% gestegen.

CEO

Himanshu Baid (56 yo)

29.2yrs

Tenure

₹171,781,000

Compensatie

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Himanshu Baid	CEO, MD & Director	29.2yrs	₹171.78m	11.59% ₹ 30.6b
Jugal Baid	Founder & Non Executive Director	no data	₹1.43m	2.25% ₹ 5.9b
Naresh Vijayvergiya	Chief Financial Officer	3.3yrs	₹11.21m	geen gegevens
Avinash Chandra	Company Secretary & Compliance Officer	9.5yrs	₹1.88m	geen gegevens
Rishi Baid	Joint MD & Executive Director	no data	₹166.82m	12.38% ₹ 32.7b
Vishal Baid	President of Corporate Sales & Marketing	2.6yrs	₹18.39m	1.66% ₹ 4.4b
P. Rastogi	Assistant Vice President of Finance & Accounts	no data	geen gegevens	geen gegevens
Hemant Bhalla	Senior Vice President of Domestic Sales & Marketing	no data	₹5.79m	geen gegevens
Pankaj Gupta	President of R&D	no data	₹5.61m	geen gegevens
Manish Sardana	President of Sales & Marketing - India	no data	₹8.61m	geen gegevens

6.4yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van POLYMED is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Himanshu Baid	CEO, MD & Director	29.7yrs	₹171.78m	11.59% ₹ 30.6b
Jugal Baid	Founder & Non Executive Director	29.7yrs	₹1.43m	2.25% ₹ 5.9b
Rishi Baid	Joint MD & Executive Director	29.7yrs	₹166.82m	12.38% ₹ 32.7b
Vimal Bhandari	Non-Executive Independent Director	less than a year	geen gegevens	geen gegevens
Amit Khosla	Non-Executive Independent Director	4.4yrs	₹1.60m	geen gegevens
Devendra Mehta	Non-Executive Independent Chairman	19.5yrs	₹1.63m	geen gegevens
Mukulika Baid	Non-Executive Director	10.3yrs	₹1.43m	3.02% ₹ 8.0b
Sonal Mattoo	Non-Executive Independent Director	4.3yrs	₹1.45m	geen gegevens
Alessandro Balboni	Non-Executive Non Independent Director	6.5yrs	₹29.90m	geen gegevens
Ambrish Mithal	Independent Director	2.6yrs	₹1.45m	geen gegevens

8.4yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van POLYMED wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.4 jaar).

Poly Medicure Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Poly Medicure Limited Appoints Vimal Bhandari as Non-Executive and Independent Director

Poly Medicure Limited Announces Board Cassation

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure Limited, Annual General Meeting, Sep 26, 2024

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure Limited, Annual General Meeting, Sep 28, 2023

Recent updates

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Poly Medicure Limited to Report Q2, 2025 Results on Oct 28, 2024

Poly Medicure Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 8.3% to ₹2,198

Poly Medicure Limited Appoints Vimal Bhandari as Non-Executive and Independent Director

Poly Medicure Limited Announces Board Cassation

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Dividend of ₹3.00 announced

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure Limited, Annual General Meeting, Sep 26, 2024

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 16%

Poly Medicure Limited has filed a Follow-on Equity Offering in the amount of INR 10 billion.

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Poly Medicure Limited to Report Q1, 2025 Results on Jul 22, 2024

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Price target increased by 12% to ₹1,950

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Full year 2024 earnings: EPS exceeds analyst expectations

Poly Medicure Limited Recommends Dividend for the Financial Year 2023-24

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited to Report Q4, 2024 Results on May 17, 2024

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Price target increased by 9.4% to ₹1,718

Price target increased by 7.5% to ₹1,620

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Poly Medicure Limited to Report Q3, 2024 Results on Jan 31, 2024

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Poly Medicure Limited to Report Q2, 2024 Results on Nov 04, 2023

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Upcoming dividend of ₹3.00 per share at 0.2% yield

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Poly Medicure Limited, Annual General Meeting, Sep 28, 2023

Insufficient new directors

Joint MD & Executive Director recently sold ₹146m worth of stock

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Price target increased by 18% to ₹1,299

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 18%

Poly Medicure Limited to Report Q1, 2024 Results on Aug 07, 2023

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Investor sentiment improves as stock rises 16%

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Full year 2023 earnings: EPS exceeds analyst expectations

Poly Medicure Limited Proposes Dividend for the Financial Year 2022-23

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: ₹5.21 (vs ₹3.60 in 3Q 2022)

Poly Medicure Limited to Report Q3, 2023 Results on Jan 28, 2023

Price target increased to ₹1,021

Price target increased to ₹1,021

Second quarter 2023 earnings released: EPS: ₹4.53 (vs ₹3.99 in 2Q 2022)

Poly Medicure Limited to Report Q2, 2023 Results on Nov 04, 2022

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Investor sentiment improved over the past week

Poly Medicure Limited Appoints Ambrish Mithal as Independent Director

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Upcoming dividend of ₹2.50 per share

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Poly Medicure Limited Recommends Dividend for the Year Ended March 31, 2022

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹2.81 (vs ₹3.92 in 1Q 2022)